AVE 0.00% 0.3¢ avecho biotechnology limited

marketing is the key to poh growth, page-29

  1. 379 Posts.
    Thanks, Karicoum. My point re cash was that Dr.O., in her presentation, noted that the POH business plan expected the Company to become cash generative in 2014 - 3 years away. We know from the yearend figures plus the $7m raised that total cash pot available to fund that time, from 1/1/11, is $10million. From that they have to fund ongoing OXY development (total costs previously estimated at $30m total) and the Elixia launch and ongoing support.

    On any definition that programme requires very careful cash management, with probably a bit of luck thrown in.
    By 'cash strapped' I meant they can only have a very limited, tight resource for consumer launch & development.

 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $9.507M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
56 96190952 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 59101557 17
View Market Depth
Last trade - 16.12pm 07/08/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.